We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card
Product News

bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card

bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card
Product News

bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

bioMérieux has created a new Fungal Susceptibility Card for susceptibility testing of Candida species and Cryptococcus neoformans.

The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.

Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations.

Early diagnosis and prompt treatment are the key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardized and rapid yeast susceptibility testing.

The VITEK 2 AST-YS07 Fungal Susceptibility Card, which replaces VITEK 2 AST-YS06, complements the current antifungals - amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole - with micafungin, an echinocandin active against Candida species, further extending the capabilities of the VITEK 2 and helping to ensure that the correct treatment is swiftly initiated.

Advertisement